Immuno-Oncology Diagnostics Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates:Including Executive/Consultant Guides and Customized Forecasting/Analysis 2021 to 2025
Report Overview:
Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. COVID-19 changes the focus of research.
This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity and the surprising impact of COVID-19 on what might seem to be an unrelated area.
A revolution in cancer therapy is underway. New therapy based on using the body’s natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.
The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
- 1. Introduction and Market Definition
- 1.1 What are Immuno-Oncology Diagnostics?
- 1.2 Immuno-oncology – the looming cure
- 1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
- 1.3 Market Definition
- 1.3.1 Market Size
- 1.3.2 Currency
- 1.3.3 Years
- 1.4 Methodology
- 1.4.1 Authors
- 1.4.2 Sources
- 1.5 U.S. Medical Market and laboratory Testing - Perspective
- 1.5.1 U.S. Medicare Expenditures for Laboratory Testing
- 2. Immunotherapy – Guide to Immune Technologies
- 2.0 The Immune System
- 2.0.1 Innate immune system
- 2.0.1.1 Surface barriers
- 2.0.1.2 Inflammation
- 2.0.1.3 Complement system
- 2.0.1.4 Cellular barriers
- 2.0.1.5 Natural killer cells
- 2.0.2 Adaptive immune system
- 2.0.2.1 Lymphocytes
- 2.0.2.2 Killer T cells
- 2.0.2.3 Helper T cells
- 2.0.2.4 Gamma delta T cells
- 2.0.2.5 B lymphocytes and antibodies
- 2.0.3 Tumor immunology – the immune surveillance system
- 2.1 Immuno Oncology Diagnostics
- 2.1.1 Checkpoint Assays
- 2.1.1.1 Outlook for Checkpoint Assays
- 2.1.2 Cytokine Assays
- 2.1.2.1 Outlook for Cytokine Assays
- 2.1.3 Genomic Germline
- 2.1.3.1 Outlook for Genomic Germline
- 2.1.4 Genomic Tumour
- 2.1.4.1 Outlook for Genomic Tumour
- 2.1.5 Tumor Microenviroment
- 2.1.5.1 Outlook for Tumor Micro Environment
- 2.1.6 Others
- 2.1.6.1 Outlook for Other Diagnostics
- 3. Industry Overview
- 3.1 Players in a Dynamic Market
- 3.1.1 Academic Research Lab
- 3.1.2 Diagnostic Test Developer
- 3.1.3 Genomic Instrumentation Supplier
- 3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
- 3.1.4 Pharmaceutical/Reagent Supplier
- 3.1.5 Independent Testing Lab
- 3.1.6 Public National/regional lab
- 3.1.7 Hospital lab
- 3.1.8 Physician Lab
- 3.1.9 Audit Body
- 3.1.10 Certification Body
- 4. Market Trends
- 4.1 Factors Driving Growth
- 4.1.1 Outcome potential
- 4.1.2 Companion Diagnostics
- 4.1.3 Funding
- 4.1.4 Technology Environment
- 4.1.5 Target Solutions
- 4.2 Factors Limiting Growth
- 4.2.1 Complex Role of Diagnostics
- 4.2.2 Clinical Trials Role
- 4.2.3 Protocols
- 4.3 Diagnostic Technology Development
- 4.3.1 Combinations - Issues and Complexity
- 4.3.2 Shifting Role of Diagnostics
- 4.3.3 Multiplexing and Foundation One
- 4.3.4 The Disruption Dynamic
- 4.3.5 The Race for Biomarkers
- 4.3.6 The Next Five Years
- 5. Cancer Immuno-Oncology Diagnostics Recent Developments
- 5.1 Recent Developments – Importance and How to Use This Section
- 5.1.1 Importance of These Developments
- 5.1.2 How to Use This Section
- OncoDNA use HalioDx to Expand into North America
- Adaptive Biotechnologies, Q2 Solutions Sign Agreement for ImmunoSeq Assay
- Qiagen Expands Immuno-Oncology Portfolio
- Immune Profiling System Redirected to Fight COVID-19
- IncellDx Awarded PD-L1 Detection Patent
- FDA Approves CDx for Trastuzumab
- Promega Nabs CE Mark for Microsatellite Instability IVD
- ArcherDx partners with AstraZeneca for Immuno-Oncology
- Germline Results Guides Precision Therapy
- Agilent PD-L1 Assay Gets FDA Approval
- Bayer, OrigiMed Form Companion Diagnostic Development Alliance
- Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy
- SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological
- Signatures
- Biocare Medical Launches 7 Novel IVD Antibodies
- Oncocyte to Acquire Insight Genetics for $12M
- Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
- Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
- Generex to Merge with NuGenerex Immuno-Oncology
- Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop
- Companion Diagnostics for Cancer Therapies
- Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative
- Breast Cancer
- Icon Acquires MolecularMD
- Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
- Tumor Mutational Burden as Predictor of Immunotherapy Success
- 6. Profiles of Key Immunotherapy Companies
- 10X Genomics
- Abbott Laboratories
- Abcam
- Adaptive Biotechnologies
- Aethlon Medical
- Agena Bioscience
- Angle plc
- Apocell
- ARUP Laboratories
- Beckman Coulter
- Becton Dickinson
- Bioarray Genetics
- BioCartis
- Biocept
- Biodesix Inc
- BioFluidica
- BioGenex
- bioMérieux
- Bio-Rad
- Bio-Techne
- Bristol-Myers Squibb
- Cancer Genetics
- Caris Molecular Diagnostics
- CellMax Life
- Charles River Laboratories
- Chronix Biomedical
- Circulogene
- Clearbridge BioMedics
- Clinical Genomics
- Cynvenio
- Cytolumina Technologies Corp.
- CytoTrack
- Dako (Agilent)
- Diagnologix LLC
- Epic Sciences
- Exosome Diagnostics
- Fluidigm Corp
- Fluxion Biosciences
- Foundation Medicine
- Freenome
- Genomic Health
- GenomOncology
- GRAIL
- Guardant Health
- HalioDx
- Horizon Discovery
- HTG Molecular Diagnostics
- iCellate
- Illumina
- Incell Dx
- Inivata
- Integrated Diagnostics
- Invivoscribe
- Leica Biosystems
- Luminex
- MDx Health
- Merck & Co., Inc
- MIODx
- Molecular MD
- MRM Proteomics Inc
- Myriad Genetics/Myriad RBM
- Nanostring
- Natera
- Neogenomics
- New Oncology
- Oncocyte
- Ortho Clinical Diagnostics
- Perkin Elmer
- Personal Genome Diagnostics
- Pfizer
- Promega
- Protagen Diagnostics
- Qiagen
- Quanterix
- Rarecells SAS
- Roche Diagnostics
- Siemens
- Silicon Biosystems
- SkylineDx
- SRI International
- Sysmex
- Thermo Fisher
- Trovagene
- Vortex Biosciences
- 7. The Global Market for Immuno-Oncology Diagnostics
- 7.1 Global Market Overview by Country
- 7.1.1 Table – Global Market by Country
- 7.1.2 Chart - Global Market by Country
- 7.2 Global Market by Assay Type - Overview
- 7.2.1 Table – Global Market by Assay Type
- 7.2.2 Chart – Global Market by Assay Type – Base/Final Year Comparison
- 7.2.3 Chart – Global Market by Assay Type – Base Year
- 7.2.4 Chart – Global Market by Assay Type – End Year
- 7.2.5 Chart – Global Market by Assay Type – Share by Year
- 7.2.6 Chart – Global Market by Assay Type – Segments Growth
- 8. Global Immuno-Oncology Diagnostic Markets – By Assay Type
- 8.1 Checkpoint
- 8.1.1 Table Checkpoint – by Country
- 8.1.2 Chart - Checkpoint Growth
- 8.2 Cytokine
- 8.2.1 Table Cytokine – by Country
- 8.2.2 Chart - Cytokine Growth
- 8.3 Germline Genetic
- 8.3.1 Table Germline Genetic – by Country
- 8.3.2 Chart - Germline Genetic Growth
- 8.4 Genetic Tumor
- 8.4.1 Table Genetic Tumor – by Country
- 8.4.2 Chart - Genetic Tumor Growth
- 8.5 Tumor Microenvironment
- 8.5.1 Table Tumor Microenvironment – by Country
- 8.5.2 Chart – Tumor Microenvironment Growth
- 8.6 Other
- 8.6.1 Table Other – by Country
- 8.6.2 Chart - Other Growth
- 9. Appendices
- 9.1 FDA Cancer Drug Approvals by Year
- 9.2 Clinical Trials Started 2010 to 2016
- 9.3 Prevalence of Cancer Treatments
- Table of Tables
- Table 1 List of Cancers by Mortality
- Table 2 Lab Spending 2014 to 2024
- Table 3 Overview of Innate and Adaptive Immunity
- Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment
- Table 5 FDA Approved Companion diagnostics in Cancer treatment
- Table 6 Market Players by Type
- Table 7 Five Factors Driving Growth
- Table 8 Three Factors Limiting Growth
- Table 9 - Global Market by Region
- Table 10 Global Market by Assay Type
- Table 11 Checkpoint by Country
- Table 12 Cytokine by Country
- Table 13 Germline Genetic by Country
- Table 14 Genetic Tumor by Country
- Table 15 Tumor Microenvironment by Country
- Table 16 Other by Country
- Table of Figures
- Figure 1 Cancer Death Rates – USA, CDC
- Figure 2 Clinical Lab Spending 2014 to 2024
- Figure 3 Helper T Cell Roles
- Figure 4 Antibody Diagram
- Figure 5 Macrophages attack a Cancer Cell
- Figure 6 The Tumour Micro Environment
- Figure 7 Comparing IO Diagnostic and Traditional Testing
- Figure 8 Growth rates of IO DiagnosticTechnologies
- Figure 9 Global Market Density Chart
- Figure 10 Global Market by Assay Type - Base vs. Final
- Figure 11 Global Market by Assay Type Base Year
- Figure 12 Global Market by Assay Type End Year
- Figure 13 Assay Type Share by Year
- Figure 14 Assay Type Segments Growth
- Figure 15 Checkpoint Growth
- Figure 16 Cytokine Growth
- Figure 17 Germline Genetic Growth
- Figure 18 Genetic Tumor Growth
- Figure 19 Tumor Microenvironment Growth
- Figure 20 Other Growth
- Figure 21 FDA Cancer Drug Approvals by Year
- Figure 22 Clinical Trials for Immunotherapy by Year
- Figure 23 Pie Chart of Prevalence of Cancer Treatments
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook